StockNews.com started coverage on shares of Nabriva Therapeutics (NASDAQ:NBRV – Free Report) in a research report sent to investors on Wednesday morning. The firm issued a hold rating on the biotechnology company’s stock.
Nabriva Therapeutics Stock Performance
Shares of NBRV stock opened at $0.00 on Wednesday. The company has a debt-to-equity ratio of 0.12, a quick ratio of 0.52 and a current ratio of 0.85. The firm has a market cap of $6,403.00, a P/E ratio of 0.00 and a beta of 1.53. Nabriva Therapeutics has a twelve month low of $1.22 and a twelve month high of $8.45.
Nabriva Therapeutics Company Profile
Read More
- Five stocks we like better than Nabriva Therapeutics
- What Does a Stock Split Mean?
- 3 Small-Cap Stocks on the Way to Bigger and Better Days
- Differences Between Momentum Investing and Long Term Investing
- MarketBeat Week in Review – 9/30 – 10/4
- How to Buy Cheap Stocks Step by Step
- Top Streaming Companies: Who’s Winning the Battle?
Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.